Strategic Partnerships Opportunity to expand collaborations with external biotech and pharmaceutical companies through Haystack MRD's tumor-informed ctDNA MRD capabilities, leveraging recent and ongoing research partnerships to co-develop diagnostic and companion diagnostic solutions.

Clinical Community Active engagement at major oncology events (SGO, ASCO GI, SSO) indicates strong value in presenting real-world data and peer validation; use these touchpoints to initiate pilots with clinics and cancer centers seeking MRD-guided treatment decisions.

Precision Diagnostics High-precision, tumor-informed MRD testing positions Haystack MRD as a potential companion diagnostic or post-therapy surveillance tool; target academic centers and community oncology practices expanding MRD adoption.

Funding & Growth Current revenue range and recent $56M funding suggest readiness for scale; sales opportunities exist in expanding commercial footprint, payer discussions, and co-development deals with larger diagnostic players.

Strategic Alliances Existing collaborations with TriSalus, Lisata, Rutgers Cancer Institute and others highlight a pattern of partnering for therapeutic monitoring; leverage these relationships to propose integrated MRD solutions aligned with specific clinical trials and therapeutic programs.